Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL9176732 | 0.92 | LMNA (0.52) | LMNATSHRALBTK1PKM | |
| Doxribtimine SCHEMBL341619 | 0.83 | LMNA (0.59) | LMNATSHRALBTK1PKM | |
| Doxribtimine SCHEMBL2164592 | 0.82 | TK1 (0.53) | LMNATSHRALBTK1PKM | |
| Doxribtimine SCHEMBL17985772 | 0.79 | LMNA (0.54) | LMNATSHRALBTK1PKM | |
| Doxribtimine SCHEMBL9465657 | 0.78 | TK1 (0.51) | LMNATSHRALBTK1PKM | |
| Azaserine SCHEMBL20520234 | 0.77 | ALDH1A1 (0.41) | TSHR | |
| Doxribtimine SCHEMBL3166229 | 0.76 | TK1 (0.52) | LMNATSHRALBTK1PKM | |
| Doxribtimine SCHEMBL1164058 | 0.76 | TK1 (0.53) | LMNATSHRALBTK1PKM | |
| Doxribtimine SCHEMBL8366525 | 0.76 | TK1 (0.53) | LMNATSHRALBTK1PKM | |
| Doxribtimine SCHEMBL3155784 | 0.76 | TK1 (0.52) | LMNATSHRALBTK1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279401-A1 | T Cell Hybridomas And Related Compositions And Methods For Assaying And Modulating T Cell Receptor-Mediated Immune Responses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-04 | — | — | US | disclosed |
| EP-1802741-A4 | T CELL HYBRIDOMAS AND RELATED COMPOSITIONS AND METHODS FOR ASSAYING AND MODULATING T CELL RECEPTOR-MEDIATED IMMUNE RESPONSE | UNIV OREGON HEALTH & SCIENCE (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1802741-A2 | T CELL HYBRIDOMAS AND RELATED COMPOSITIONS AND METHODS FOR ASSAYING AND MODULATING T CELL RECEPTOR-MEDIATED IMMUNE RESPONSE | Oregon Health and Science University (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006010020-A2 | T CELL HYBRIDOMAS | OREGON HEALTH AND SCIENCE UNIVERSITY (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-0651819-A1 | METHODS FOR HUMAN MONOCLONAL ANTIBODY PRODUCTION | IMMUNET (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1993019197-A1 | HUMAN MONOCLONAL ANTIBODIES AND METHODS FOR HUMAN MONOCLONAL ANTIBODY PRODUCTION | IMMUNET (US) | 1993-09-30 | — | — | WO | disclosed |
| US-4950598-A | Process for making T cell hybridomas | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1990-08-21 | — | — | US | disclosed |